KROS: Keros Therapeutics Inc

KROS Nouvelles

• Investing 12:05 Keros Therapeutics doses first patient in Phase 3 MDS trial
• Reuters 14:41 Fat, not muscle: drugmakers in race for next weight-loss breakthrough
• Benzinga 18:37 Keros Therapeutics' Quiet Near-Term Outlook Overshadows Pipeline Potential: Analyst - Keros Therapeutics (NASDAQ:KROS)
• Investing 09:05 BofA cuts Keros Therapeutics stock rating, price target to $18
• Investing 19:17 Keros directors face significant shareholder dissent
• Investing 11:01 Keros Therapeutics to return $375 million to shareholders
• Investing 20:16 Keros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare Conference
• Benzinga 16:54 Keros Therapeutics Stops PAH Drug Development, Shrinks Workforce By 45% - Keros Therapeutics (NASDAQ:KROS)
• Investing 10:57 Keros Therapeutics halts PAH drug development, cuts workforce
• Investing 17:48 Keros secures Glass Lewis support for director nominees
• Investing 12:14 ADAR1 calls for Keros to release review results before vote
• Investing 12:28 Keros Therapeutics Highlights Commitment to Maximizing Stockholder Value
• Seeking Alpha 18:13 Keros Therapeutics (KROS): Strategic Alternatives Could Bring About Value Creation
• Benzinga 17:51 Keros Therapeutics Goes Up For Sale On Heels Of Stockholder Rights Plan - Keros Therapeutics (NASDAQ:KROS)
• Benzinga 16:12 Crude Oil Falls Over 4%; Keros Therapeutics Shares Jump - CarMax (NYSE:KMX), Keros Therapeutics (NASDAQ:KROS)
• Benzinga 14:05 PriceSmart Posts Better-Than-Expected Earnings, Joins Enact Holdings, DexCom And Other Big Stocks Moving Higher On Thursday - Enact Holdings (NASDAQ:ACT), DexCom (NASDAQ:DXCM)
• Seeking Alpha 22:25 Keros Therapeutics: Losing Its Lead Drug Is Bad Medicine (NASDAQ:KROS)
• Seeking Alpha 14:01 Fidelity Select Health Care Portfolio Q4 2024 Review (Mutual Fund:FSPHX)